AbbVie Inc. said on Sept. 28 the U.S. health regulator approved the company’s once-daily oral medicine Qulipta for the preventive treatment of migraine in adults, adding a third product to the drugmaker’s arsenal of therapies for severe headaches.
© AbbVie Inc. All rights reserved.Migraine headaches can be reduced in frequency and severity by atopant, an oral therapy developed by AbbVie, according to data presented at the 2021 American Headache Society’s (AHS) Annual Scientific Meeting.
Cambridge, Massachusetts-based Praxis Precision Medicines raised about $110 million in a Series C financing, led by Eventide Asset Management,
British scientists analyzing data from a widely used Covid-19 symptom-tracking app have found there are six distinct types of the disease, each distinguished by a cluster of symptoms.
Teva Pharmaceutical Industries Ltd.’s anti-CGRP drug fremanezumab hit the target reducing monthly migraine days in a late-stage study.
A smartphone-based relaxation app could help migraine sufferers reduce the number of headaches they get each month, a small study suggests.
Eli Lilly and Co.’s migraine treatment Emgality became the first drug to gain U.S. approval for decreasing the frequency of episodic cluster headache attacks.
Eli Lilly and Co. pulled ahead in a three-way race with Amgen Inc. and Teva Pharmaceutical Industries Ltd. in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that the company’s therapy can completely prevent headaches in a small percentage of patients.
Teva Pharmaceutical Industries Ltd. will stop developing the migraine drug Ajovy for treating cluster headaches after finding the treatment was unlikely to meet the main goal of a late-stage trial.
